In June, Lipigon Pharmaceuticals signed a development and licensing agreement worth nearly SEK 1 billion. Today, the Umeå-based company has relocated to a newly renovated 250 square meter facility tailored to their needs. Lipigon’s CEO, Stefan K. Nilsson, views these achievements as “pivotal strides in the company’s ongoing journey of growth and innovation.”
Lipigon Pharmaceuticals from Umeå is celebrating the signing of a development and license agreement for its clinical-stage drug candidate Lipisense® with Leaderna Therapeutics worth an estimated USD 91 million.
“We are delighted with this agreement and look forward to working with Leaderna on the future development of Lipisense®”, says Stefan K Nilsson, CEO of Lipigon. The new agreement specifically involves the development and licensing of the drug in Greater China.
At an Extraordinary General Meeting, Urban Paulsson was elected a regular board member of Umeå-based Lipigon Pharmaceuticals AB. Urban Paulsson’s business law expertise entails a strengthening of the Board and is an important component for the company’s continued successful development.
The UBI alumni Lipigon Pharmaceuticals announced yesterday that the startup has entered into a target validation research agreement with Munich-based antisense therapeutics company Secarna Pharmaceuticals. The goal is to co-develop a best-in-class drug for treatment of severe forms of dyslipidemia and related lipid disorder driven diseases.
Lipigon Pharmaceuticals, an Umeå University spin-off and UBI alumni company has attracted two top talents to join the work in their board. Gisela Sitbon is nominated for the position as Chairman of the Board.
The eight consecutive Biotech Umeå Investment Day attracted almost 30 Swedish and international investors to Blasierummet at Grand Hotel on the 2 of February 2017 in Stockholm. One of the most appreciated aspects of the event was the flexibility to arrange additional ad-hoc partnering meetings and the size and atmosphere at the event.
